C4 Therapeutics, Inc.

We are thrilled to welcome Steve Hoerter to our Board of Directors! We’ve developed our Board to be comprised of industry experts across clinical development, business development and scientific discovery, and Steve’s proven expertise in strategically advancing oncology programs to market will be essential in our evolution to a fully integrated biotech delivering new #TPD medicines to patients. Steve brings over three decades of executive management, commercial and board experience, most recently serving as the president and chief executive officer of Deciphera Pharmaceuticals, transforming it from a clinical stage to commercial company. Learn more in our latest release: https://lnkd.in/eHYtXBTz

We will participate in a fireside chat at the Jefferies London Healthcare Conference on November 20. #JefferiesHealthcare

Our annual Thanksgiving potluck is always a fun opportunity to join together over a delicious meal, including some of our team's own home-cooked dishes, and honor the compassion we have for each other and commitment to the work that we do.

Our Chief People Officer Kelly Schick will join a panel discussion at the Leap HR Emerging Biopharma conference in Boston to discuss the strategic role HR leaders have in helping the business plan and meet the evolving needs of the company. Learn more: https://bit.ly/4fqno3K

It’s National #STEM Day! As catalysts in the field of #TPD, we take inspiration from collaboration, sparking each other’s ideas to advance our science and accelerate our collective impact on patients, including early career colleagues who are interested in paving a path in STEM. Our team takes pride in sharing our love of science to the future catalysts of the world, including through our annual Project Onramp internship program. We encourage anyone interested in STEM to pursue this impactful career! #NationalSTEMDay

#TPD program update: We announced that our partner Betta Pharmaceuticals Co., Ltd. has dosed the first patient in the Phase 1 clinical trial of CFT8919, an orally bioavailable degrader of #EGFR L858R in non-small cell lung cancer (#NSCLC), in Greater China.     C4T designed CFT8919 to target EGFR mutations in NSCLC, which are particularly common in NSCLC patients of Asian heritage. Our team is thrilled to see this therapy enter clinical development. Learn more in our latest release: https://bit.ly/3YABPeQ

At the American Society of Hematology’s (ASH) Annual Meeting in December we will present data from the ongoing Phase 1/2 trial of our orally bioavailable MonoDAC® degrader, cemsidomide, in multiple #myeloma and non-Hodgkin’s #lymphoma. Learn more in our latest release: https://bit.ly/3UCAFyr #ASH24

Find us at the ASAP BioPharma Conference in Boston! Our SVP of strategic alliances and business development, Isabel Chiu, and Susan Green, executive director and head of R&D strategic collaborations at Biogen, will present on our #TPD collaboration to develop new treatments for patients. More on the event here: https://bit.ly/4f3Yrvp

We announced third quarter 2024 financial results and recent business highlights. Read more here: https://bit.ly/40rUsV4

Our team is at the #TPD and Induced Proximity Summit in Boston to deliver presentations on our leadership in developing highly catalytic orally bioavailable degraders and participate in panel discussions with our industry colleagues on topics like the state of the TPD field and best practices in managing strategic partnerships. Learn more: https://bit.ly/3tHso1l